PMID- 10488483
OWN - NLM
STAT- MEDLINE
DCOM- 19991012
LR  - 20131121
IS  - 0029-5566 (Print)
IS  - 0029-5566 (Linking)
VI  - 38
IP  - 5
DP  - 1999
TI  - [Hyperthyroidism in a premature infant due to transplacental passage of maternal 
      thyrotropin receptor antibodies].
PG  - 156-9
AB  - The duration of the stimulating effect of transplacental transferred 
      thyrotropin-receptor-antibodies (TRAb) is discussed by the example of a 23 years 
      old woman suffering from Graves' disease with a severe hyperthyroidism. She 
      became pregnant six weeks after the diagnosis was obtained and then discontinued 
      her antithyroid medication on her own responsibility. On a check-up in the 20th 
      week of pregnancy, a hyperthyroidism was once more found, leading to a therapy 
      with propylthiouracil, which however, was again interrupted by the patient a few 
      weeks later. In the 32nd week, she gave birth to a male child that already 
      presented with distinct signs of thyrotoxicosis and developed a continuous 
      deterioration of the condition, including a tachycardia with up to 190 beats per 
      minute, fever, tremor and a respiratory disorder. Assay of the newborn serum 
      revealed a severe hyperthyroidism. The TRAb level was 180 U/l (normal range < 
      15). A therapy with propranolol and prednisolone was initiated, leading to a 
      significant improvement of the general condition. Nevertheless, after 12 days, 
      there was still no notable decrease of the hormone levels. Therefore an 
      antithyroid medication was started, which caused normal thyroid hormone levels 
      within 9 days. However, after the therapy was stopped, a hyperthyroidism was 
      again observed within one week, requiring another, low-dose antithyroid 
      medication, which was administered for 26 days. After this period, the TRAb level 
      was down to 25 U/l and no more hyperthyroidism was found. The biological 
      half-life of the TRAb was 20 days in our case.
FAU - Rink, T
AU  - Rink T
AD  - Abteilung fur Nuklearmedizin, Stadtkrankenhaus Hanau, Deutschland. 
      Rink@em.uni-frankfurt.de
FAU - Wieg, C
AU  - Wieg C
FAU - Schroth, H J
AU  - Schroth HJ
FAU - Helisch, A
AU  - Helisch A
FAU - Bertram, U
AU  - Bertram U
LA  - ger
PT  - Case Reports
PT  - English Abstract
PT  - Journal Article
TT  - Fruhgeborenenhyperthyreose durch diaplazentar ubertragene TSH-Rezeptor-Antikorper 
      der Mutter.
PL  - Germany
TA  - Nuklearmedizin
JT  - Nuklearmedizin. Nuclear medicine
JID - 7609387
RN  - 0 (Anti-Arrhythmia Agents)
RN  - 0 (Antithyroid Agents)
RN  - 0 (Autoantibodies)
RN  - 0 (Cardiotonic Agents)
RN  - 0 (Receptors, Thyrotropin)
RN  - 3S12J47372 (Dobutamine)
RN  - 8KQ660G60G (Carbimazole)
RN  - 9PHQ9Y1OLM (Prednisolone)
RN  - 9Y8NXQ24VQ (Propranolol)
SB  - IM
MH  - Adult
MH  - Anti-Arrhythmia Agents/therapeutic use
MH  - Antithyroid Agents/therapeutic use
MH  - Autoantibodies/*blood
MH  - Carbimazole/therapeutic use
MH  - Cardiotonic Agents/therapeutic use
MH  - Dobutamine/therapeutic use
MH  - Female
MH  - Graves Disease/blood/*immunology
MH  - Humans
MH  - Hyperthyroidism/drug therapy/*etiology
MH  - Infant, Newborn
MH  - *Infant, Premature
MH  - Male
MH  - *Maternal-Fetal Exchange
MH  - Prednisolone/therapeutic use
MH  - Pregnancy
MH  - Pregnancy Complications/blood/*immunology
MH  - Prenatal Exposure Delayed Effects
MH  - Propranolol/therapeutic use
MH  - Receptors, Thyrotropin/*immunology
MH  - Tachycardia/drug therapy/etiology
MH  - Thyrotoxicosis/drug therapy/*etiology
EDAT- 1999/09/17 00:00
MHDA- 1999/09/17 00:01
CRDT- 1999/09/17 00:00
PHST- 1999/09/17 00:00 [pubmed]
PHST- 1999/09/17 00:01 [medline]
PHST- 1999/09/17 00:00 [entrez]
PST - ppublish
SO  - Nuklearmedizin. 1999;38(5):156-9.